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ABSTRACT 
Agomelatine (AGM) is an antidepressant drug. Its extensive hepatic first-pass metabolism coupled with low biological half-life shows 5% 
absolute bioavailability on oral administration. Polymeric nanoparticles (PNPs) have capability to efficiently penetrate the skin barrier and BBB 
so as to effectively reach the drug to site of action. Polymeric nanoparticles of drug (AGM-PNPs) with PLGA polymer were prepared by 
nanoprecipitation method followed by solvent evaporation. The particle size, polydispersity index, zeta potential and % entrapment efficiency 
of the optimized formulation were found to be compliant with the desired standards. DSC, FT-IR and XRD methods of instrumental analysis 
confirmed the formation of AGM-PNPs. Matrix–type transdermal patch containing AGM-PNPs (formulation TP 2) and AGM (formulation TP 1) 
were prepared by a solvent evaporation method using a film former machine. In-vitro drug release from patch formulations TP1 and TP2 were 
found to be 47.41 ± 1.78 and 70.16 ± 1.74. The drug release data of the in-vitro drug release study was analysed with kinetic models zero order, 
first order release kinetic model, Higuchi model, Korsmeyer-peppas model. In ex-vivo skin permeation studies, transdermal patch formulation 
containing AGMPNPs (TP 2) shown least lag time as compared to  transdermal patch containing agomelatine (TP-1).  
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INTRODUCTION 
Depression is a neuronal disorder with symptoms of reduced 
mood, lack of interest in day today life, low energy, low 
confidence in behavior, feelings of wrongdoing, poor 
concentration. It has affected about 350 million people in the 
world. As per the report of the world mental health survey 
conducted in 17 countries, 1 in 20 people has been found to 
suffer from depressive episodes last year. Anxiety is the 
common symptom often associated with depression and is 
the leading cause for suicidal tendencies leading to 1 million 
deaths annually. It has been observed that both genders are 
susceptible to depressive episodes but females are more 
prone to the development of depression than males (Marcus 
et al. 2012). The continuous treatment for a longer period of 
time is highly desirable for depression treatment as the 
reoccurrence of depressive episodes is high (Dubovsky et 
al. 2009, Debodinat et al. 2010). To minimize the risk of 
recurrence, drug treatment for a period of one year is 
recommended (Kennedy et al. 2009, Demyttenaere et al. 
2011).  
As per the survey, around 40% patients discontinue the drug 
treatment within the period of one month while 56% 
patients shows non-compliance to treatment schedules 
within 4 months (Demyttenaere et al. 2011). It is well-
known that tolerability and mental problems decline the 
capability of antidepressants, and that a steady state drug 
plasma concentration is critical for management of 
depression (Serna et al. 2010). 
Agomelatine is an antidepressant drug. It is a melatonergic 
MT1/MT2 receptor agonist and it has 5-HT2C receptor 
antagonist activity. By antagonizing 5-HT2C receptors, it 
increases noradrenaline and dopamine release specifically in 
the frontal cortex (Buoli et al. 2014). A tablet dosage form 
of AGM is commercially available.  The extensive hepatic 
first-pass metabolism coupled with low biological half-life 
shows 5% absolute bioavailability on oral administration of 
AGM (Debodinat et al. 2010). Due to extensive hepatic first-
pass metabolism of drug, a patient on AGM therapy requires 
a liver function test (Demyttenaere et al. 2011). For 
effective treatment of depression, daily medication is 
required but irregular dose intake may occur due to 
psychological illness. It can be overcome by development of 
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transdermal drug delivery system to maintain steady state 
drug plasma concentration.  
Blood-brain barrier (BBB) hinders passage of drug in central 
nervous system (CNS). BBB is comprised of continuing layer 
of particular endothelial cells associated with tight junctions. 
The intricate barrier regulates and restricts systemic 
delivery of drugs to CNS. Numerous advanced approaches 
have been discovered to augment passage of drugs through 
BBB. Nanoparticles are promising carriers for drug delivery 
to the brain due to distinctive features comprising small size, 
higher drug solubility, the capability for multi-functionality, 
and precise drug release profile and potential for targeted 
drug delivery (Hersh et al. 2016). 
Five layers of skin epidermis from the deepest to superficial 
are stratum basale also called stratum germinativum, 
stratum spinosum, stratumgranulosum, stratum lucidum, 
and stratum corneum.  The uppermost layer of skin is 
stratum corneum and is the physical barrier for passage of 
drug.  Epidermal layer exists below stratum corneum. 
Epidermis is hydrophobic in nature. Numerous techniques 
have been developed to increase penetration of drug across 
skin including the nanoparticulate drug delivery systems 
(Tomoda et al. 2014). 
Polymeric nanoparticles (PNPs) have capability to efficiently 
penetrate the skin barrier and BBB so as to effectively reach 
the drug to site of action. Size of PNPs ranges from 1 to 1000 
nm. PNPs are able to carry a significant amount of drug 
across BBB and also provides controlled release profiles. 
Biodegradable polymers poly (lactic-co-glycolic acid) (PLGA) 
and poly (lactic acid) (PLA) have been extensively 
investigated for drug delivery (Vijayan et al. 2013).  
Transdermal drug delivery system (TDDS) is a non-invasive 
method of drug delivery into systemic circulation by 
applying it on skin surface. It provides a maximum surface 
area of 1.73 m2 and provides constant sink condition. Skin 
receives one-third of circulating blood at any given time. The 
drug initially penetrates through the stratum corneum and 
then passes through the deeper epidermis and dermis 
without drug accumulation in the dermal layer. When the 
drug reaches the dermal layer, it becomes available for 
systemic absorption via the dermal microcirculation. TDDS 
has many advantages over other conventional routes of drug 
delivery. It can provide a non-invasive alternative to 
parenteral routes, thus circumventing issues such as needle 
phobia. The drugs susceptible to hepatic first-pass 
metabolism can be effectively administering using 
transdermal drug delivery system (Alkilani et al. 2015). 
MATERIAL AND METHOD 
Materials 
Agomelatine (AGM) was received as a gift sample from 
Mehta API Pvt. Ltd., Mumbai, India. Polymer PLGA (50:50) 
was supplied as a gift sample by Evonik Degussa India Pvt. 
Ltd., Mumbai, India. Pluronic F-68 was kindly received as gift 
sample from Himedia Laboratories Pvt. Ltd., Mumbai, India 
was used as a stabilizer. Poly vinyl alcohol was received as a 
gift sample from Himedia Laboratories Pvt. Ltd., Mumbai, 
India. Ethanol was purchased from Changshu Hongsheng 
Fine Chemicals Ltd. Propylene glycol was purchased from 
SRL Chemical Laboratory Pvt. Ltd., Mumbai, India. Transcutol 
HP was supplied as a gift sample by Gattefosse (France). 
Oleic acid (OA) was purchase from Loba Chemie Pvt. Ltd., 
Mumbai, India. N- Methyl-2-Pyrrolidone (NMP) was 
purchase from S.D. Fine chem Ltd. (Mumbai, India). Isopropyl 
myristate (IPM) was supplied as a gift sample by Mohini 
Organics Pvt. Ltd., Mumbai, India. Dimethyl formamide 
(DMF) was purchased from Ranbaxy Fine Chemicals Ltd.  
Method 
Preparation of agomelatine polymeric nanoparticles 
(AGM-PNPs)  
Polymeric nanoparticles of drug with polymer were 
prepared by nano-precipitation method followed by solvent 
evaporation. The resulting oil in water (o/w) emulsion was 
formed using different drug: polymer ratio.  As shown in 
table 1, an accurately weighed amount of AGM and PLGA was 
dissolved in 2 mL mixture of (Acetone1.3 mL+ ethanol 0.7 
mL) to form an organic phase (O). It was drop wise added 
with help of syringe into aqueous phase (W) consisting of 
Pluronic F-68 %w/v as a stabilizer and then organic solvent 
was evaporated under continuous magnetic stirring at room 
temperature for overnight. In the next step, surfactant 
solution was homogenized using a high-speed homogenizer 
(IKA Ultra turrex T18, Germany) as shown in figure 1 at 
speed between 7,000-12,000 rpm followed by probe 
sonication (Sonics Vibra Cell ™) at 80 % amplitude for 5 
minutes. The AGM-PNPs were recovered by centrifugation 
using a refrigerated centrifuge at 16,000 rpm for 60 min at 4 
℃, washed with distilled water to eliminate or remove 
additives (Joshi et al. 2010).  
The AGM-PNPs pellet obtained after centrifugation was 
vortexes (Impact, Icon Instruments Company, India) after 
addition of 5 %w/v mannitol as a cryoprotectant, followed 
by bath sonication (PCi, India) for 5 minutes and filled in 
glass vials. The vials were freeze-dried at minus 40 °C and 
850 mm/Hg vacuum to obtain a stable dry product. The 
freeze drying was carried out for 72 hours using a lyophilizer 
(Mac ®, Macro Scientific Works, India) to obtain a free-
flowing AGM-PNPs powder. The product was stored in 
refrigerator in airtight glass container sealed with parafilm.  
The experimental procedure was repeated with the varied 
drug : polymer ratio and varying concentrations of 
surfactant. Scale-up experiments were performed to 
determine large scale application.  
Preparation of transdermal patch by a solvent 
evaporation method using film former machine  
Matrix–type transdermal patch containing AGM-PNPs (TP 2) 
and AGM (TP 1) were prepared by a solvent evaporation 
method using a film former machine (Bhalekar et al. 2016).
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Table 1 Preparation of transdermal patch containing AGM-PNPs 
Name of ingredients 
Formulations 
TP 1 TP 2 
Agomelatine 625 mg - 
AGM-PNPs - Weight equivalent to 625 mg drug 
Polyvinyl alcohol 250 mg 250 mg 
Polyvinyl pyrrolidone -K30 250 mg 250 mg 
Polyethylene glycol 400 6 %v/v  6 %v/v  
Transcutol-HP 5 %v/v 5 %v/v 
Solvent system 33% PG in ethanol (10 mL) 33% PG in ethanol (10 mL) 
 
As shown in table 1, polymers were accurately weighed and 
dissolved in a specified amount of 33% PG in ethanol 
(optimized solvent) and allowed to form a uniform 
dispersion by stirring at 100 rpm for 60 minutes. PEG 400 
was added as a plasticizer to obtain flexibility and strength 
to film. 5% T-HP was used as a penetration enhancer. An 
accurately weighed amount of AGM and nanoparticles 
equivalent to 625 mg AGM was added to resultant 
dispersion of polymer and mixed well using magnetic stirrer. 
The final dispersion was then spread onto the glass surface 
of the film former with the help of the dragger. It was 
allowed to air dry at room temperature. The patches of 2 cm 
x 2 cm (4 cm2) were cut and kept in desiccators until further 
use. The patches containing AGM & AGM-PNPs based patch 
were prepared with 33% PG in ethanol. 
EXPERIMENTAL WORK 
Evaluation of AGM-PNPs 
Determination of particle size and polydispersity index 
(PDI)  
Photon correlation spectroscopy (PCS) is a technique used to 
determine the mean particle size diameter and the width of 
the particle size distribution expressed as PDI. The 
measurement using PCS is based on the light scattering 
phenomena in which statistical intensity fluctuations of 
scattered light from the particles in measuring cell are 
measured. These fluctuations are due to the random 
movement of particles in dispersion medium because of the 
brownian motion of dispersion medium molecules (distilled 
water). 
Zetasizer Nano ZS 90, Malvern Instrument (Malvern, UK) 
was used to measure the particle size. The instrument was equipped with a laser beam (λ = 633 nm). The scattered light 
detector is positioned at an angle of 173º. This detection 
angle is known as the back scatter detection and it has the 
advantages of improved sensitivity and the possibility of 
measuring a wide range of sample concentrations. The measuring range of this device is between 0.6 nm to 6 μm. 
Samples were diluted with double distilled water to an 
appropriate concentration. The average particle size 
diameter and PDI are given from at least 30 runs (Gupta et 
al, 2010, Wissing et al. 2004). 
Determination of zeta potential  
The zeta potential parameter is used to characterize the 
charge on the surface of the nanoparticles that plays a vital 
role in determining the stability of the formed nanoparticles. 
Zetasizer Nano ZS 90 (Malvern Instruments, UK), which 
calculates the zeta potential by determining the 
electrophoretic mobility and then applying the henry 
equation was used to determine zeta potential of the 
formulations (F1-F9). The electrophoretic mobility is 
obtained by performing an electrophoresis experiment on 
the sample and measuring the velocity of particles using 
laser doppler velocimetry (Gupta et al, 2010, Wissing et al. 
2004). 
Determination of entrapment efficiency                 
The nanoparticle suspension was subjected to centrifugation 
at 16,000 rpm for 60 minutes at 4 ℃. The method for 
determination of entrapment efficiency was based on the 
amount of AGM recovered from supernatants. It was 
assumed that the rest of the AGM used during preparation 
had been encapsulated. The blank used was the supernatant 
obtained after centrifugation of dummy nanoparticles 
(without drug) at 10,000 rpm for 30 minutes at 15 ℃. 
Equation 2 was used to calculate entrapment efficiency 
(Elshafeey et al. 2017). 
 
 
                                        Total drug content − Amount of free drug in supernatant 
       % EE =                                                                                                                                                × 100   --- (2) 
                                        Total drug content 
  
Characterization of lyophilized AGM-PNPs 
The characterization of lyophilized AGM-PNPs was 
performed using Fourier transform infrared (FT-IR) 
spectroscopy studies, differential scanning calorimetry (DSC) 
studies, and X-ray diffraction (XRD) spectroscopy studies. 
Fourier transform infrared (FT-IR) spectroscopy studies  
The sample of lyophilized AGM-PNPs of optimized 
formulation (F9) was triturated and mixed well with IR 
grade potassium bromide in 1:100 ratio. The mixture was 
introduced in the sample holder of FT-IR instrument and 
scanned in the range from 4000 to 400 cm-1 to obtain the 
spectrum. The obtained spectrum was compared with the 
spectrum obtained for AGM and physical mixture of AGM 
with a PLGA (Singh et al. 2015). 
Differential scanning calorimetry (DSC) studies  
The sample of lyophilized AGM-PNPs of optimized 
formulation (F9) was kept in desiccator for 24 h before 
thermal analysis. The accurately weighed sample, 5 mg was 
hermetically sealed in aluminum crucible and heated at a 
constant rate of 10 ℃/min over a temperature range of 40 to 
400 ℃. An inert atmosphere was maintained by purging 
nitrogen gas at a flow rate of 50 mL/min. An empty 
aluminum pan was used as a reference (Singh et al. 2015). 
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X-ray diffraction (XRD) spectroscopy studies  
X-ray diffraction spectrum of lyophilized AGM-PNPs of 
optimized formulation (F9) was recorded by a diffractogram 
using Cu-Kα line as a source of radiation at a voltage of 35 Kv 
and current 25 mA. The sample was measured in the 2θ 
angle range between 3-80 ⁰ and 0.0053 step size (Singh et 
al. 2015). 
Surface morphology study of lyophilized AGM-PNPs 
using scanning electron microscopy (SEM)  
The surface morphology of lyophilized AGM-PNPs was 
visualized using SEM (Zeiss SEM EVO-18, Carl Zeiss 
Microscopy). The water suspended nanoparticles were 
mounted on a glass slide as a thin smear and left to dry. The 
particles on dried glass slide were subjected to gold 
sputtering and the slide was attached on SEM holder using a 
double side carbon tape mounted on an aluminum stud. The 
SEM photomicrographs were captured by operating at an 
accelerating voltage of 20 kV electron beam at desired 
magnification (Vijayan et al. 2013). 
Evaluation of transdermal patch 
a) Appearance  
The transdermal patch formulation TP 1 and TP 2 were 
visually inspected for color, texture, and homogeneity (Singh 
et al. 2016).   
b) Average patch thickness  
Thickness of transdermal patch formulation TP 1 and TP 2 
were measured by using a screw gage micrometer at three 
different points on the patches. Average values and standard 
deviation values of three readings were calculated for each 
transdermal patch formulation TP 1 and TP 2 (Singh et al. 
2016). 
c) Weight variation  
A set of three patches from transdermal patch formulation 
TP 1 and TP 2 having an area of 4 cm2 were weighed on a 
digital balance and the mean values were calculated. The 
tests were performed on transdermal patches which were 
dried at 60 ℃ for 4 h prior to testing (Singh et al. 2016). 
d) Folding endurance   
The test was carried out to check efficiency of plasticizer and 
strength of patch prepared using different polymers. The 
folding endurance is defined as the number of folds required 
to break any polymeric patch. The folding endurance was 
measured manually by repeatedly folding a small strip of the 
patch 2 cm × 2 cm (4 cm2) at the same place until it was 
broken. The number of times the patch could be folded at the 
same place without breaking or cracking gave the value of 
folding endurance. Three patches of each type were taken for 
the test sample (Singh et al. 2016). 
e) Percent moisture uptake  
The percent moisture absorption test was carried out to 
check the physical stability and integrity of transdermal 
patch in high humid conditions. The prepared transdermal 
patches (4 cm2) were individually weighed accurately and 
exposed to 85 ± 5% relative humidity in a desiccator 
containing 100 mL of saturated solution of potassium 
chloride at room temperature. During this period, the films 
were weighed at regular time intervals of 24, 48, and 72 h. 
The percent moisture absorption was determined by using 
equation 6 (Singh et al. 2016).   
 
                                                               Final weight of patch – Initial weight of patch 
  Moisture uptake (%) =                                                                                                              x 100 --- (6) 
      Initial weight of patch 
 
f) Percentage moisture content  
This test was also carried to check the integrity of 
transdermal patch under dry conditions. The individual 
transdermal patches (4cm2) were kept in a desiccator 
containing fused anhydrous calcium chloride at room 
temperature. During this period, the transdermal patches 
were weighed at regular time intervals of 24, 48, and 72 h. 
The percentage of moisture content was determined by using 
equation 7 (Singh et al. 2016). 
 
                                                      Initial weight of patch – Final weight of patch 
   Moisture content (%) =                                                                                                  × 100 --- (7) 
                                                                  Initial weight of patch 
 
g) Drug content uniformity  
The transdermal patch formulation TP 1 and TP 2 were 
transferred into a graduated glass stopper flask containing 
100 mL phosphate buffer saline pH 7.4. The flask was shaken 
for 24 h in a mechanical shaker followed by bath sonication 
for 15 minutes. The solution was filtered and 1 mL sample 
was diluted to 10 mL with phosphate buffer saline pH 7.4. The absorbance was measured at λmax of drug using the 
placebo patch solution as blank and the drug content was 
calculated (Bhalekar et al. 2016). 
h) In-vitro drug release studies  
Franz diffusion cell was employed for in-vitro 
characterization of transdermal formulations. This is a 
reliable method for the prediction of drug transport across 
skin from topical formulations. The receptor compartment 
of the diffusion cell was filled with 20 mL of phosphate 
buffered saline pH 7.4 contatining 1 %v/v tween 80, and in-
vitro drug release studies were carried out using synthetic 
cellophane membrane. The prepared transdermal patches 
were applied on to the membrane in the donor 
compartment. The assembly was constantly maintained at 
32.0 ± 0.5 °C at 100 rpm. Samples (1.0 mL aliquots) were 
then withdrawn at suitable time intervals (0, 1, 2, 4, 6, 8, 10, 
12, 16, 20, 24, 36, 48 h) and replenished with an amount of 
medium to maintain the receptor phase volume to 20 mL. 
The samples were analyzed spectrophotometrically at 277 
nm (Singh et al. 2016).                          
Release kinetic models  
In order to understand the mechanism and kinetics of drug 
release, the drug release data of the in-vitro drug release was 
analyzed with various kinetic models like zero order, first 
order, Higuchi, Korsmeyer peppas model and correlation co-
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efficient values were calculated for the linear curves by 
regression analysis of above plots (Shabbier et al. 2017). 
 i) Ex-vivo skin permeation studies 
The ex-vivo skin permeation from a transdermal patch 
formulation TP 1 and TP 2 were studied. 
Isolation of skin  
Rat abdominal skin was obtained after sacrificing the male 
Wistar rats. The hair of the abdominal region was removed. 
Full-thickness skin was surgically removed and the dermis 
side was wiped with isopropyl alcohol to remove residual 
adhering fat. The skin was soaked in water at 60 ℃ for 1 min 
and washed with water, wrapped in aluminium foil and 
stored at (minus) 20 ℃ until used (Singh et al. 2016).                             
Ex-vivo skin permeation studies 
Ex-vivo skin permeation studies were performed by the 
Franz diffusion cell with a receptor compartment capacity 
20 mL and effective diffusion area 3.14 cm2. The skin was 
brought to room temperature by thawing.  The skin was 
hydrated by placing in phosphate buffer saline pH 7.4 with 1 
%v/v tween 80 overnight before use and then mounted 
between the donor and receiver compartment of the Franz 
diffusion cell, where the stratum corneum side faced the 
donor compartment. Patches were placed over the skin and 
covered with paraffin film in order to ensure that the 
patches do not dislodge from the skin during the test. The 
receptor compartment of the diffusion cell was filled with 
phosphate buffer pH 7.4 containing 1 %v/v tween 80. The 
whole assembly was fixed on a magnetic stirrer, and the 
solution in the receptor compartment was constantly and 
continuously stirred using magnetic beads at 100 rpm; the 
temperature was maintained at 32 ± 0.5°C. The samples 
were withdrawn at pre-determined time intervals (0, 1, 2, 4, 
6, 8, 10, 12, 16, 20, 24, 36 and 48 h) and analyzed for drug content spectrophotometrically at the λmax of the drug. The 
cumulative amounts of drug permeated per square 
centimeter of patches were plotted against time. Flux, 
permeability coefficient & enhancement ratio were 
calculated by using equation (1), (2) and (3) respectively. 
Permeation data analysis 
A) The flux (Jss) (mg/cm2/h) was calculated from the 
slope of the plot of the cumulative amount of drug 
permeated per cm2 of skin at steady state against time 
using linear regression analysis. (Haq et al. 2018)
 
                     
                                          Slope at steady state  
Flux (mg/cm2/h) =                                                          --- (1) 
                                 (Jss)                         Effective diffusion area 
                     
B) Permeability coefficient (Kp) were determined by using (Haq et al. 2018).                                                     
                                                              Flux (Jss) 
Permeability (Kp) =                                                                        --- (2) 
                                    Concentration of drug in donor phase 
  
C) Enhancement ratio (ER) was determined by using (Haq et al. 2018). 
 
                                                 Flux with AGM - PNPs based transdermal patch 
    Enhancement ratio =                                                                                          ---                (3) 
                       (ER)                                Flux with AGM transdermal patch 
 
j) Skin irritation test  
The study was performed on the basis of the approval of the 
Institutional Animal Ethical Committee. The animals (Wistar 
rats) were grouped and housed in cages, with free excess to 
standard laboratory diet and water. The dorsal abdominal 
skin of the rats was shaved carefully avoiding peripheral 
damage, before 24 h of conducting the study. The 
transdermal patch was applied onto the nude skin and 
covered with a non-sensitizing microporous tape. A 0.8 %v/v 
aqueous solution of formalin was applied as a standard skin 
irritant. The animals were applied with a new patch each day 
up to 7 days. The formulation was removed after 7 days; a 
score of erythema was recorded and was compared with 
standard. The score of erythema was read and recorded by 
the Draize scoring method as score 0 for no erythema, score 
1 for very slight erythema (light pink), score 2 for well-
defined erythema (dark pink), score 3 for moderate to severe 
erythema (light red), and score 4 for severe erythema (dark 
red) (Singh et al. 2016). 
k) Animal study  
Animal 
Male Wistar rats of weight (220 – 250 g) were procured from 
the central animal facility of UDPS, R.T.M.N.U. Nagpur and 
used for antidepressant activity of the developed 
transdermal patch containing AGM-PNPs (TP 2). Animals 
were kept in plastic cages and had free access to food and 
water and maintained at proper temperature and humidity. 
All the experimental protocols were duly approved by the 
Institutional Animal Ethics Committee (IAEC), UDPS, Nagpur 
(India). All the experiments were performed in accordance 
with the guidelines of the Committee for the Purpose of 
Control and Supervision of Experiments on Animals 
(CPCSEA), India (Steru et al. 1985; Singh et al. 2016; 
Indulkar 2018). 
Protocol for the antidepressant study 
Male Wistar rats were divided into three groups each 
containing four rats (n=4). The first group was treated with 
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saline solution and was considered as control. The second 
group was treated with AGM tablet oral solution (the 2 mg 
drug was homogeneously suspended in 1 %w/v solution of 
hydroxyl ethyl cellulose.) considered as a standard. The third 
group was treated with a transdermal patch containing AGM-
PNPs (2mg).  
Tail suspension test 
The post-treatment groups of the rats were suspended on 
the metal rod stand 50 cm above the table top by the 
adhesive tape placed approximately 1cm from the tip of the 
tail. Immobility time was recorded during a five minute 
periods. The rats were observed after a time interval of 1, 2, 
6, 12 and 24 h for their immobility time period. Once the 
experimental time (5 min.) has elapsed, the rats should be 
returned to the home cage and the tape should be removed 
from the tail by tenderly pulling it off. The total immobility 
period were expressed in seconds. 
 
Table 2 Experimental protocol for animal study 
Sr. No. Experimental protocols  Treatments  No. of animals  
1 Wistar rats (Control group) Saline solution 04 
2 Wistar rats (Standard group)  AGM Tablet solution (Dose- 2 mg) 04 
3 Wistar rats (Test group) A transdermal patch containing 
AGM-PNPs (Dose- 2 mg) 
04 
  Total  n=12 
    
Evaluation  
The immobility time period of patch treated animals was 
compared with normal control and standard groups at 
different time interval 1, 2, 6, 12 and 24 h.   
Stability study  
Stability study of transdermal patch formulation TP 2  
The transdermal patch formulation TP 2 was selected and 
the stability studies were carried out at 25 ±2 ºC, 60 ±5 % RH 
conditions, stored in stability chamber (Remi Instruments 
Ltd, Mumbai, India). The patches were packed in aluminium 
foil and kept in above condition for a period of one month. 
The transdermal patch formulation TP 2 was analysed 
periodically for drug content and in-vitro drug release 
(Lalani et al. 2012; Katara et al. 2017). 
RESULTS AND DISCUSSION 
Characterization of AGM-PNPs 
Determination of particle size and  
The particle size and polydispersity index of the AGM-PNPs 
are important characters in determining the capability of the 
particles to cross the BBB. The particle size and PDI of all 
formulations were obtained using Zetasizer Nano ZS 90 and 
the results are depicted in table 3 and particle size and PDI of 
optimized formulation are shown in Figure 1. 
 
Table 3 Particle size and PDI of formulations 
Sr. no. Formulation codes Particle size (nm) PDI 
1 F1 98.4 ± 3.85 0.216 ± 0.02 
2 F2 134.2 ± 3.67 0.376 ± 0.01 
3 F3 111.5 ± 2.85 0.314 ± 0.06 
4 F4 107.1 ± 2.98 0.254 ± 0.02 
5 F5 160.5 ± 3.99 0.401 ± 0.04 
6 F6 112.3 ± 3.35 0.21 ± 0.03 
7 F7 101.2 ± 3.45 0.147 ± 0.06 
8 F8 127.3 ±  4.56 0.345 ± 0.04 
9 F9 104.5 ± 3.98 0.135 ± 0.02 
Table data were expressed as mean ± S.D. (n=3) 
 
Fig. 1 Particle size and PDI of optimized formulation (F9) 
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Determination of zeta potential 
The zeta potential of the AGM-PNPs is important to determine the stability and uptake mechanism of the particles inside the 
body. The zeta potential values of formulations are shown in table 4 and zeta potential values of optimized formulation (F9) are 
shown in figure 2.  
Table 4 Zeta potential of formulations 
Sr. No. Formulation codes Zeta potential (mV) 
1 F1  (-) 12 ± 0.52 
2 F2  (-) 11 ± 0.67 
3 F3  (-) 11.9 ± 0.98 
4 F4  (-) 12.1 ± 0.23 
5 F5  (-) 10.7 ± 0.39 
6 F6  (-) 12.7 ± 0.54 
7 F7  (-) 13 ± 0.19 
8 F8  (-) 9.1 ± 0.36 
9 F9  (-) 13.3 ± 0.46 
Table data were expressed as mean ± S.D. (n=3) 
 
Fig. 2 Zeta potential of optimized formulation (F9) 
 
Determination of percent entrapment efficiency (%EE) 
The results of %EE of all formulations are mentioned in 
table 5. 
Table 5 % Entrapment efficiency of all formulations 
Sr. No. Formulation Codes % EE  
1 F1 65 ± 3.36 
2 F2 72 ± 4.51 
3 F3 70.5 ± 2.26 
4 F4 68.3 ± 3.98 
5 F5 79.5 ± 4.85 
6 F6 84.2 ± 1.19 
7 F7 80 ± 2.36 
8 F8 69 ± 3.65 
9 F9 83.6 ± 4.12 
Table data were expressed as mean ± S.D. (n=3) 
The particle size (104.5 ±3.98 nm), PDI (0.135 ±0.02),  zeta 
potential (-) 13.3 ±0.48 mV and %EE (83.6 ±4.12%)  of the 
F9 formulation was found to be optimum and thus the 
formulation F9 was considered as optimized formulation 
and subjected to further studies. 
 
Characterization of lyophilized AGM-PNPs 
Differential scanning calorimetry (DSC) study 
The DSC studies for AGM, PLGA polymer and AGM-PNPs 
were conducted in an inert nitrogen environment. In the DSC 
studies of AGM, an endotherm at 109.53 ºC with onset at 
108.40 ºC and endset at 111.37 ºC was observed (Zhang et 
al. 2018). The enthalpy of endothermic transaction was 
found to be (minus) 75.24 J/g in case of PLGA polymer a 
glass transition temperature at 45.86 ºC with onset at 42.76 
ºC and end set 48.19 ºC was observed (Kapoor et al. 2015). 
The enthalpy for glass transition was found to be (minus) 
7.26 J/g. The AGM-PNPs prepared using PLGA polymer has 
shown the first endotherm at 42.12 ºC which was nearer to 
the value of glass transition temperature of PLGA. The 
second endotherm was observed at 107.65 ºC with an onset 
at 88.58 ºC and endset at 105.16 ºC the enthalpy of 
endothermic transaction was found to be (minus) 4.16 J/g. 
The second endotherm in DSC thermograph was observed 
since the drug was made available to the heating process 
after the polymer has been subjected to the glass transition 
process. Hence the second endotherm confirmed the melting 
of AGM. It confirmed preformation of AGM-PNPs. DSC 
thermograph of AGM, PLGA and AGM-PNPs are shown in 
figure 3 (a), (b) and (c) respectively.  
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Fig. 3 DSC thermograph of AGM, PLGA and AGM-PNPs (a) DSC thermograph of AGM (b) DSC thermograph of PLGA (c) DSC 
thermograph of AGM-PNPS 
 
X-ray diffraction (XRD) study 
X-ray diffraction spectra of AGM, PLGA polymer and AGM-
PNPs are shown in figure 4 (a), (b), (c) respectively. XRD 
spectrum of AGM has shown crystalline peaks (Zhang et al. 2018). The crystalline peaks were observed at 2θ=6.64, 8.83, 
9.40, 10.69, 11.46, 12.76, 13.18, 17.32, 19.14, 20.35, 22.25, 
24.38, 25.47 with high intensity. In case of the XRD spectrum 
of PLGA polymer, a diffused pattern was observed and no 
single crystalline peak was observed. The amorphous 
characteristics of PLGA polymer were confirmed (Makadia 
et al. 2011). The AGM-PNPs as shown the partial crystalline 
peaks of AGM and partial diffused pattern of PLGA polymer, 
but the number of crystalline peaks and their intensity were 
reduced also the intensity was found to be reduced. It 
confirmed the adsorption of AGM on the PLGA polymer. 
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Fig. 4 X-RD spectrum of AGM, PLGA and AGM-PNPs (a) X-RD spectrum of AGM (b) X-RD spectrum of PLGA (c) X-RD spectrum 
of AGM-PNPs 
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Fourier transform infrared (FT-IR) spectroscopy study 
The FT-IR spectrum of AGM, PLGA and lyophilized AGM-PNPs of optimized formulation (F9) are shown in figure 5 (a), (b), (c) 
respectively. 
 
Fig. 5 FT-IR spectrum of AGM, PLGA and AGM-PNPs (a) FT-IR spectrum of AGM (b) FT-IR spectrum of PLGA (c) FT-IR spectrum 
of AGM-PNPs 
The FT-IR spectrums were recorded for AGM, PLGA and 
lyophilized AGM-PNPs. The FT-IR spectrum of AGM shown 
stretching vibrations of N-H (3254.93 cm-1), aromatic C-H 
stretching (3034.8 cm-1), -CH3 stretching (2838.20 cm-1), the 
carbonyl stretching vibration of C=O (1640.49 cm-1) and 
aromatic C=C stretching (1599.02 cm-1) (Barmpalexis et al. 
2018). The FT-IR spectrum of PLGA shown O-H stretching 
(3647.45 cm-1), C=O stretching (1749.47 cm-1), C-H 
asymmetric stretching (2946.32 cm-1) and C-O stretching 
(1273.04 cm-1) (Sousa et al. 2015). The AGM-PNPs has 
shown the absence of peaks representing the characteristics 
stretching frequencies of AGM. It concluded that the 
successfully formation of AGM-PNPs. The characteristics 
peaks of PLGA were observed in AGM-PNPs, it confirmed the 
formation of nanoparticles and coating of drug by PLGA 
polymer.
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d) Scanning electron microscopy                                                                                   
 
Fig. 6 SEM images of optimized formulation (F9) 
 
The SEM photomicrographs of sample solution (F9 
formulation) were obtained and as shown in figure 6. The 
photomicrographs revealed that the surface was uniform 
with appearance of spherical shape AGM-PNPs. 
Evaluation of transdermal patch containing AGM (TP 1) 
and transdermal patch containing AGM-PNPs (TP 2) 
a) Physical appearance 
The transdermal patch formulation TP 1 and TP 2 were 
evaluated for the appearance (color, texture, and 
homogeneity) and the results are mentioned in table 6.
 
Table 6 Physical appearance of transdermal patch formulation TP 1 and TP 2 
Formulations Colour Texture Homogeneity 
TP 1 transparent Smooth Obtained 
TP 2 Transparent Slightly gritty Obtained 
 
b) Average thickness of transdermal patch 
The average thickness of transdermal patch formulation TP 1 and TP 2 were determined and the results are mentioned in table 
7. 
Table 7 Average thickness of transdermal patch formulation TP 1 and TP 2 
Formulations Thickness (mm) Average patch 
thickness (mm)  Trial I Trial II Trial III 
TP 1 0.05 0.06 0.06 0.056 ± 0.005 
TP 2 0.07 0.09 0.08 0.08 ± 0.01 
Table data were expressed as mean ± S.D. (n=3) 
c) Weight variation 
Weight variations of transdermal patch formulation TP 1 and TP 2 were determined and the results are mentioned in table 8. 
 
Table 8 Weight variation of transdermal patch formulation TP 1 and TP 2 
Formulations Weight (mg) Average weight 
           (mg)  Trial I Trial II Trial III 
TP1 36.9 35.1 37.5 36.5 ±1.24 
TP2 33.6 36.4 35.2 35.06 ±1.40 
Table data were expressed as mean ± S.D. (n=3) 
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d) Folding endurance 
Folding endurance of transdermal patch formulation TP 1 and TP 2 were determined and the results are mentioned in table 9. 
Table 9 Folding endurance of transdermal patch formulation TP 1 and TP 2 
Formulations Folding endurance  
Average folding endurance 
 Trial I Trial II Trial III 
TP1 151 160 158 156 ±4.72 
TP2 155 169 161 161 ±7.02 
            Table data were expressed as mean ± S.D. (n=3) 
        
e) Percent moisture uptake 
Percent moisture uptakes of transdermal patch formulation TP 1 and TP 2 were determined and the results are mentioned in 
table 10. 
      Table 10 Percent moisture uptake transdermal patch formulation TP 1 and TP 2 
Formulations Moisture uptake (%) Average moisture 
uptake (%)  
 Trial I Trial II Trial III 
TP1 1.89 1.61 1.73 1.74 ± 0.14 
TP2 1.76 1.98 1.82 1.85 ± 0.113 
         Table data were expressed as mean ± S.D. (n=3)        
f) Percent moisture content 
The percent moisture content of transdermal patch formulation TP 1 and TP 2 were determined and the results are mentioned 
in table 11. 
Table 11 Percent moisture content of transdermal patch formulation TP 1 and TP 2 
Formulations Moisture content (%) Average moisture content 
(%) 
 Trial I Trial II Trial III 
TP1 2.16 2.42 1.88 2.15 ± 0.27 
TP2 1.97 2.25 2.04 2.08 ± 0.14 
Table data were expressed as mean ± S.D. (n=3) 
g) Drug content uniformity 
Drug content uniformity of transdermal patch formulation TP 1 and TP 2 were determined and the results are mentioned in 
table 12. 
Table 12 Drug content uniformity of transdermal patch formulation TP 1 and TP 2 
Formulations Drug content (mg) Average drug 
content (mg)  Trial I Trial II Trial III 
TP1 24.5 24.1 23.8 24.13 ± 0.35 
TP2 24.2 24.4 24.7 24.43 ± 0.25 
Table data were expressed as mean ± S.D. (n=3) 
   
h) Comparison of in-vitro drug release of transdermal patch formulation TP 1 and TP 2 
The percent cumulative drug release (% CDR) by in-vitro drug release of the transdermal patch with the AGM (TP 1) was 
compared with that of the transdermal patch with AGM-PNPs (TP 2) as shown in table 13 and illustrated in figure 7. 
 
 
 
 
 
Shinde et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):126-144  
ISSN: 2250-1177                                                                                  [138]                                                                                 CODEN (USA): JDDTAO 
Table 13 Comparison of in-vitro drug release of TP 1 and TP 2 
Sr. 
No. 
Time interval (h) In-vitro drug release from the patch formulations (% CDR) 
 TP 1 TP 2 
1 0 0 0 
2 1 0.49 ± 0.06  0.43 ± 0.05 
3 2 0.75 ± 0.04 0.81 ± 0.08 
4 4 1.55 ± 0.08 2.88 ± 0.10 
5 6 2.84 ± 0.12 6.10 ± 0.23 
6 8 5.76 ± 0.56 11.54 ± 0.54 
7 10 9.77 ± 1.87 14.59 ± 0.99 
8 12 11.84 ± 1.63 21.41 ± 1.45 
9 16 22.56 ± 1.11 33.08 ± 1.13 
10 20 27.74 ± 1.97 39.31 ± 2.16 
11 24 33.98 ± 2.05 50.66 ± 2.36 
12 36 42.62 ± 2.26 62.05 ± 1.67 
13 48 47.41 ± 1.78 70.16 ± 1.74  
Table data were expressed as mean ± S.D. (n=3) 
 
 
Fig. 7 In-vitro drug release plot of transdermal patch formulation TP1 and TP2 
 
Drug release kinetic study 
The drug release data of the in-vitro drug release study was 
analysed with various kinetic models like zero order, first 
order, higuchi model, korsmeyer-peppas model. Coefficient 
correlation values were calculated for the linear curves by 
regression analysis of the above plots. The regression 
coefficient was found to be highest in the korsmeyer-peppas 
model with the value of R2= 0.9738 indicating that drug 
release from the AGM-PNPs followed korsmeyer-peppas 
model. Results obtained in drug release kinetic studies are 
given in table 14 and figure 8 (a), (b), (c) and (d) for 
transdermal patch formulation TP 2. 
 
Table 14 Drug release kinetic studies of in-vitro drug release 
Sr. No. Model R2 values 
TP 1 TP 2 
1 Zero order 0.9466 0.9536 
2 First order 0.9659 0.9672 
3 Higuchi 0.9036 0.9216 
4 Korsmeyeer- Peppas 0.9672 0.9738 
 
Shinde et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):126-144  
ISSN: 2250-1177                                                                                  [139]                                                                                 CODEN (USA): JDDTAO 
 
Fig. 8(a) Zero order release kinetic plot       Fig. 8 (b) First order release kinetic plot 
 
Fig. 8 (c) Higuchi release kinetic plot             Fig. 8(d) Korsmeyer-Peppas kinetic plot 
 
i) Ex-vivo skin permeation studies 
The amount of drug permeated (ex-vivo skin permeation) of 
transdermal patch formulation TP 1 and TP 2 was compared 
and the results are shown in table 15 and illustrated in figure 
9. The amount of drug permeated after 24 h from 
transdermal patch formulation TP 1 and TP 2 was found to 
be 8.67 mg and 13.66 mg respectively. 
 
 Fig. 9 Ex-vivo drug permeation study of transdermal patch 
formulation TP 1 and TP 2 
Table 15 Amount of drug permeated from transdermal 
patch formulation TP 1 and TP 2 (mg/cm2/h) 
Sr. 
No. 
Time Interval 
(h) 
 
 TP 1 TP 2 
1 0 0 0 
2 1 0.13 ± 0.02 0.11 ±0.01 
3 2 0.22 ± 0.05 0.21 ± 0.03 
4 4 0.40 ± 0.04 0.66 ± 0.02 
5 6 0.86 ± 0.09 1.62 ± 0.08 
6 8 1.54 ± 0.04 3.15 ± 0.06 
7 10 2.86 ± 0.02 3.83 ± 0.03 
8 12 3.83 ± 0.08 5.80 ± 0.10 
9 16 6.11 ± 0.11 8.98 ± 0.04 
10 20 7.01 ± 0.23 10.24 ± 0.35 
11 24 8.67 ± 0.12 13.60 ± 0.39 
12 36 10.77 ± 0.44 16.36 ± 0.29 
13 48 12.05 ± 0.19 18.10 ± 0.15 
             Table data were expressed as mean ± S.D. (n=3)
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Permeation data analysis 
The transdermal patch formulation containing AGM-PNPs 
(TP 2) has shown the least lag time as compared to 
transdermal patch containing AGM (TP 1) in ex-vivo 
permeation studies is shown in Table 42. The flux values, 
permeability coefficient and enhancement ratio were found 
to be enhanced in case of TP 2 as compared to TP 1 is shown 
in table 16 and table 17 and depicted in figure 10(a) and 
figure 10(b). It is due to the smallest size of nanoparticles 
which has high accessibility across the skin. 
 
Table 16 Permeation data analysis of transdermal patch formulation TP 1 and TP 2 
Flux (Jss)  
(µg/cm2/h) 
Permeability coefficient (Kp) 
(cm/h×103) 
Enhancement ratio 
(ER) 
TP 1 TP 2 TP 1 TP 2 TP 1 TP 2 
131.52 ±2.56 206.05 ± 3.41 5.26 8.24 1 1.57 
Table data were expressed as mean ± S.D. (n=3) 
 
Fig. 10(a) Flux values of TP 1 and TP 2 (b) Lag time of TP 1 and TP 2 
 
Table 17 Lag time of transdermal patch formulation TP 1 
and TP 2 
                                                Lag time (h) 
TP 1 TP 2 
7.77 ±0.19 5.77 ±0.11 
Table data were expressed as mean ± S.D. (n=3) 
j) Skin irritation test 
Table 18 Results of skin irritation study of the transdermal 
patch formulation TP 2 
Day Parameter 
Standard     
      Test 
 
1 2 1 2 
Day 0 
Erythema 0 0 0 0 
Edema 0 0 0 0 
Day 7 
Erythema 3 3 1 1 
Edema 2 3 0 0 
                       
The seven-day skin irritation study revealed that test 
formulation, a transdermal patch formulation TP 2 showed 
skin irritation score (erythema and edema) of less than 1. 
From the Draize method of scoring, the standard group (0.8 
%v/v formalin solution) of animals showed severe erythema 
and moderate to slight edema whereas the test animals 
(transdermal patch formulation TP 2) showed only very 
slight erythema and no edema on site of application. Results 
are depicted in figure 11(a), (b), (c) and (d) respectively. 
According to Draize et. al 1984, compounds producing scores 
of 2 or less are considered non-irritant. Hence, from the 
study, it was observed that transdermal patch formation TP 
2 was non-irritable and safe for therapeutic use. 
 
Fig. 11 (a) Transdermal Patch formulation TP 2 application 
to shaved area, (b) Skin of animal on day 0, (c) Skin of test 
group after day 7 of application of TP 2 (d) Skin of standard 
group after day 7 
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k) Animal study 
Tail suspension test (TST) 
Table 19 Effect control, treatment and standard group on total immobility time in TST 
Treatment group Total immobility period (Seconds) 
Time interval 1 h 2 h 6 h 12 h 24 h 
Saline solution 
(Control) 
155 ± 3.03 157 ± 3.95 151 ± 2.24 153 ± 2.69 150 ± 2.20 
Agomelatine tablet oral 
solution 
(Standard) 
141 ± 3.98 105 ± 1.15 139 ± 2.21 151 ± 1.19 148 ± 2.26 
Transdermal patch 
formulation TP 2  
(Test) 
153 ± 2.91 138 ± 21.99 105 ± 2.54 99 ± 3.32 97 ± 2.36 
Table data were expressed as mean ± S.D. (n=3) 
 
Above results of tail suspension test revealed that there was 
a significant reduction in total immobility period over the 
time interval of 24 h of animals by treating with 
antidepressant drug AGM. There was a significance 
difference in total immobility period in control group as 
compared to a standard group, test group. A transdermal 
patch formulation TP 2 shows a significant reduction in total 
immobility period than of oral tablet treatment. The 
transdermal patch formulation TP 2 shows sustained action 
over the 24 h and shows a significant reduction in immobility 
period of animals as compared to standard and control 
groups. The comparison between the immobility period of 
control, standard and test at various time interval is shown 
in table 19 and depicted in figure 12.   
 
 
Fig. 12 Effect of control (Saline solution), test (Transdermal patch formulation TP 2) and standard (Oral AGM tablet solution) 
on immobility time in TST 
l) Stability study 
The stability study data obtained are given in table 45. The data for in-vitro release study is shown in table 20 and graphically 
depicted in figure 13. 
Table 20 Stability study of a transdermal patch formulation TP 2 
Time period 
Drug content (%) % cumulative release 
25 ± 2 ºC 
25 ± 2 ºC 
  
Initial  97.72 ±0.19  71.86  ±1.64  
After 1 month 97.45 ±0.26 70.96 ±1.21 
Table data were expressed as mean ± S.D. (n=3) 
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Table 21 Comparison of in-vitro drug release of transdermal patch formulation TP 2 initially and after 1 month 
Sr. 
No. 
Time interval (h) In-vitro drug release from the transdermal patch 
formulation TP 2 (% CDR) 
 Initial After 1 month 
1 0 
0.00 ±0 0.00 ± 0 
2 1 
0.40 ± 0.06 0.39 ± 0.03 
3 2 
0.83 ± 0.09 0.80 ± 0.02 
4 4 
2.75 ± 0.13 2.78 ± 0.06 
5 6 
6.19 ± 0.19 6.04 ± 0.21 
6 8 
12.54 ± 0.61 12.10 ± 0.65 
7 10 
15.79 ± 0.51 15.01 ± 0.97 
8 12 
23.24 ± 1.65 22.97 ± 1.32 
9 16 
32.18 ± 2.12 31.85 ± 0.98 
10 20 
42.36 ± 1.86 41.20 ±1.65 
11 24 
51.36 ± 2.01 50.32 ± 1.46 
12 36 
64.65 ± 1.05 63.30 ± 1.50 
13 48 71.86 ± 1.64  70.96 ± 1.21 
Table data were expressed as mean ± S.D. (n=3) 
                            
 
Fig. 13 In-vitro release plots of transdermal patch 
formulation TP 2 stored at 25 ± 2 ºC and 60 ±5 % RH 
conditions 
Stability study of a transdermal patch formulation TP 2 
showed that patch was stable and there was no any 
significant change observed in drug content and % 
cumulative release at 25 ±2 ºC, 60 ±5 % RH conditions over 
a period of 1 month. 
CONCLUSION 
Agomelatine (AGM) is an antidepressant drug. Its extensive 
hepatic first-pass metabolism coupled with low biological 
half-life shows 5% absolute bioavailability on oral 
administration.  It can be overcome by development of 
transdermal drug delivery system to maintain steady state 
drug plasma concentration.  
Blood-brain barrier (BBB) hinders the passage of drug in the 
central nervous system (CNS). Numerous techniques have 
been developed to increase penetration of drug across skin 
including the nanoparticulate drug delivery systems. 
Polymeric nanoparticles (PNPs) have capability to efficiently 
penetrate the skin barrier and BBB so as to effectively reach 
the drug to site of action. Polymeric nanoparticles of drug 
(AGM-PNPs) with PLGA polymer were prepared by nano-
precipitation method followed by solvent evaporation. The 
particle size,  polydispersity index, zeta potential and % 
entrapment efficiency of the optimized formulation was 
found to be 104.5 ±3.98 nm, 0.135 ±0.02, (-) 13.3 ±0.48 mV 
and 83.6 ±4.12%  respectively. DSC, FT-IR and XRD methods 
of instrumental analysis confirmed the formation of AGM-
PNPs. In scanning electron microscopy study uniform 
spherical polymeric nanoparticles were observed.  
Matrix–type transdermal patch containing AGM-PNPs 
(formulation TP 2) and AGM (formulation TP 1) were 
prepared by a solvent evaporation method using a film 
former machine. Average folding endurance of transdermal 
patch formulation TP1 and TP2 were found to be 156 ±4.72 
to 161 ±7.02 respectively. Average moisture uptake of 
transdermal patch formulation TP1 and TP2 were found to 
be 1.74 ± 0.14 to 1.85 ± 0.113 respectively. Average drug 
content of formulations TP1 and TP2 was found to be 24.13 
± 0.35 and 24.43 ± 0.25. In-vitro drug release from patch 
formulations TP1 and TP2 were found to be 47.41 ± 1.78 and 
70.16 ± 1.74. The drug release data of the in-vitro drug 
release study was analysed with kinetic models zero order, 
first order, higuchi model, Korsmeyer-peppas model. 
Regression coefficient was found to be highest for the 
Korsmeyer-peppas model indicating that drug release from 
the AGM-PNPs followed Korsmeyer-peppas model. Amount 
of drug permeated from transdermal patch formulation TP 1 
and TP 2 at 48 h was found to be 12.05 ± 0.19 and 18.10 ± 
0.15 mg/cm2/h respectively. In ex-vivo skin permeation 
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studies, transdermal patch formulation containing AGM-
PNPs (TP 2) shown least lag time as compared to 
transdermal patch containing agomelatine (TP 1). 
Permeability coefficient (Kp) values for formulations TP1 
and TP2 were found to be 5.26 and 8.24 (cm/h×103) 
respectively. Enhancement ratio (ER) for formulations TP1 
and TP2 were found to be 1 and 1.57 respectively. In the 
seven-day skin irritation study, transdermal patch as test 
formulation (TP 2) showed skin irritation score of less than 
1. From the Draize method of scoring, the standard group 
(0.8 %v/v formalin solution) of animals showed severe 
erythema and moderate to slight edema whereas the test 
animals (transdermal patch formulation TP 2) showed very 
slight erythema and no edema on site of application. The 
results of tail suspension test revealed a significant 
reduction in total immobility period over time interval of 24 
h of animals by treating with agomelatine. A significant 
difference was observed in total immobility period in control 
group as compared to a standard group. Transdermal patch 
formulation TP 2 shown significant reduction in total 
immobility period than of oral tablet treatment. The 
transdermal patch formulation TP 2 shown sustained action 
over the 24 h and a significant reduction in immobility 
period of animals as compared to standard and control 
groups. In the Stability study of a transdermal patch, 
formulation TP 2 was found to be stable and no significant 
change was observed in drug content and % cumulative 
release at 25 ±2 ºC, 60 ±5 % RH conditions over a period of 1 
month.  
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